Howe & Rusling Inc. Raises Holdings in Becton, Dickinson and Company $BDX

Howe & Rusling Inc. boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 32.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 32,547 shares of the medical instruments supplier’s stock after buying an additional 8,036 shares during the quarter. Howe & Rusling Inc.’s holdings in Becton, Dickinson and Company were worth $5,117,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Revisor Wealth Management LLC raised its holdings in Becton, Dickinson and Company by 1.1% in the 1st quarter. Revisor Wealth Management LLC now owns 11,285 shares of the medical instruments supplier’s stock valued at $1,777,000 after buying an additional 118 shares during the period. Hudson Edge Investment Partners Inc. boosted its stake in Becton, Dickinson and Company by 4.6% during the first quarter. Hudson Edge Investment Partners Inc. now owns 44,745 shares of the medical instruments supplier’s stock worth $7,035,000 after buying an additional 1,953 shares during the period. Koshinski Asset Management Inc. boosted its stake in Becton, Dickinson and Company by 2.7% during the first quarter. Koshinski Asset Management Inc. now owns 6,729 shares of the medical instruments supplier’s stock worth $1,058,000 after buying an additional 178 shares during the period. QRG Capital Management Inc. increased its position in shares of Becton, Dickinson and Company by 64.6% during the first quarter. QRG Capital Management Inc. now owns 8,733 shares of the medical instruments supplier’s stock valued at $1,373,000 after acquiring an additional 3,429 shares during the last quarter. Finally, World Investment Advisors raised its stake in shares of Becton, Dickinson and Company by 29.0% in the 1st quarter. World Investment Advisors now owns 32,444 shares of the medical instruments supplier’s stock valued at $5,101,000 after acquiring an additional 7,303 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BDX. Barclays upped their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. The Goldman Sachs Group cut their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Finally, Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $181.00.

Becton, Dickinson and Company Trading Up 0.0%

NYSE BDX opened at $158.10 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The firm has a market cap of $43.56 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 11.19 and a beta of 0.21. The firm has a 50 day simple moving average of $147.98 and a 200-day simple moving average of $169.33. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. During the same period last year, the business posted $3.35 earnings per share. Becton, Dickinson and Company’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were paid a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 5,188 shares of company stock valued at $765,120. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.